Navigation Links
difficulties in Biological Technology

Cornerstone Therapeutics Announces Closing of Chiesi Transaction

... to commercialize our products, including difficulties relating to the manufacture of Zyflo((R)) CR ... experienced by patients taking our products; difficulties relating to clinical trials, including difficulties or delays in the completion of patient ...

Cornerstone Therapeutics Inc. Announces Record Date and Meeting Date for Special Meeting of Stockholders for Vote with Respect to Charter Amendments

... to commercialize our products, including difficulties relating to the manufacture of Zyflo CR(R) ... experienced by patients taking our products; difficulties relating to clinical trials, including difficulties or delays in the completion of patient ...

Cornerstone Therapeutics Reports Year Ended December 31, 2008 Financial Results

... to commercialize our products, including difficulties relating to the manufacture of ZYFLO CR tablets; ... experienced by patients taking our products; difficulties relating to clinical trials, including difficulties or delays in the completion of patient ...

Cornerstone Therapeutics to Host Quarter and Year Ended December 31, 2008 Conference Call

... to commercialize our products, including difficulties relating to the manufacture of ZYFLO CR(R); our ... experienced by patients taking our products; difficulties relating to clinical trials, including difficulties or delays in the completion of patient ...

Synthetech Announces Fiscal 2008 Results

... 2008 were disappointing. Production process difficulties reduced revenue and increased per unit costs, ... results. Management estimates that manufacturing difficulties related to certain customer projects reduced ... disappointed by the impact of specific production difficulties on financial results for the fourth quarter and ...

Synthetech Reports First Quarter Fiscal 2010 Results

... lower than normal margins on certain products which encountered production difficulties in prior quarters; higher than average raw material costs on certain ... the timing and amount of shipments; the resolution of manufacturing difficulties and the benefit of production efficiencies or cost reductions; the impact ...

Anadys Pharmaceuticals Receives FDA Clearance of Phase II Protocol to Study ANA598 in Combination With Interferon-Alpha and Ribavirin in HCV Patients

... candidates, its ability to successfully develop and market products, difficulties or delays in its preclinical studies or clinical trials, difficulties or delays in manufacturing its clinical trials materials, the scope and ...

Anadys Pharmaceuticals Reports Second Quarter 2009 Financial Results and Program Highlights

... candidates, its ability to successfully develop and market products, difficulties or delays in its preclinical studies or clinical trials, difficulties or delays in manufacturing its clinical trials materials, the scope and ...

Anadys Pharmaceuticals, Inc. Announces Strategic Restructuring to Focus Operations on Continuing the Advancement of ANA598

... candidates, its ability to successfully develop and market products, difficulties or delays in its preclinical studies or clinical trials, difficulties or delays in manufacturing its clinical trials materials, the scope and ...

NxStage Reports First Quarter 2009 Financial Results

... anticipated results, performance or achievements, including unanticipated difficulties in restructuring the payment terms of the Company's GE credit facility, ... products, growth in home and/or daily hemodialysis, unanticipated difficulties in achieving operational efficiencies and cost reductions, changes in ...

Anadys Pharmaceuticals Reports First Quarter 2009 Financial Results and Highlights

... candidates, its ability to successfully develop and market products, difficulties or delays in its preclinical studies or clinical trials, difficulties or delays in manufacturing its clinical trials materials, the scope and ...

Palomar and Q-MED AB Terminate International Distribution Agreement

... but are not limited to, results of future operations, technological difficulties in developing or introducing new products, the results of future research, ... the results of litigation, including patent infringement lawsuits, difficulties in collecting royalties, potential infringement of third-party ...

Cornerstone Therapeutics Provides Update on Integration Activities and Issues 2008 Revenue Guidance

... adverse side effects experienced by patients taking our products; difficulties relating to clinical trials, including difficulties or delays in the completion of patient enrollment, data collection or data ...

ANA598 Receives Fast Track Designation From the FDA for the Treatment of Chronic Hepatitis C Infection

... candidates, its ability to successfully develop and market products, difficulties or delays in its preclinical studies or clinical trials, difficulties or delays in manufacturing its clinical trials materials, the scope and ...

BMP Sunstone to Host Follow-Up 3Q08 Conference Call Due to Technical Difficulties Encountered on Tuesday's Call

... Sunstone" or the "Company"), today announced that due to the technical difficulties encountered on today's conference call, the company will hold a second ... will give callers the opportunity to ask questions since technical difficulties prevented the Company from addressing all questions on today's call. The ...

NeurogesX Reports Third Quarter 2008 Results

... and to carry out activities to commercialize NGX-4010, if approved; difficulties or delays in NeurogesX entering into commercialization partnerships ... without violating the intellectual property rights of others; other difficulties or delays in, clinical development, obtaining regulatory approval, market ...

Environmental Power Corporation and Organix, Inc. Establish Alliance to Produce High Value Soil Amendment Products

... fuels like natural gas, and our inexperience with managing such risks; difficulties involved in developing and executing a business plan; difficulties and uncertainties regarding acquisitions; technological uncertainties; ...

Anadys Pharmaceuticals Commences Dosing ANA773 in Hepatitis C Patients

... resources, its ability to successfully develop and market products, difficulties or delays in its preclinical studies or clinical trials, difficulties or delays in manufacturing its clinical trials materials, the scope and ...

Savient's Pegloticase Data in Treatment-Failure Gout Patients Presented at 72nd Annual Meeting of the American College of Rheumatology Conference

... FDA, delay achieving or failure to achieve FDA approval of pegloticase, difficulties of expanding our product portfolio through in-licensing or acquisition; ... our continuing to incur substantial net losses for the foreseeable future; difficulties in obtaining financing; potential development of alternative technologies ...

Anadys Pharmaceuticals Reports Second Quarter 2008 Financial Results and Highlights

... resources, its ability to successfully develop and market products, difficulties or delays in its preclinical studies or clinical trials, difficulties or delays in manufacturing its clinical trials materials, the scope and ...

Environmental Power Holds Ground Breaking Ceremony for Renewable Natural Gas Facility at Rio Leche Estates

... fuels like natural gas, and our inexperience with managing such risks; difficulties involved in developing and executing a business plan; difficulties and uncertainties regarding acquisitions; technological uncertainties; ...

Anadys Pharmaceuticals Reports First Quarter 2008 Financial Results and Highlights

... resources, its ability to successfully develop and market products, difficulties or delays in its preclinical studies or clinical trials, difficulties or delays in manufacturing its clinical trials materials, the scope and ...

Millennium Announces VELCADE(R) (Bortezomib) for Injection First-Quarter 2008 U.S. Net Sales

... to develop and commercialize products and services based on its work; difficulties or delays in obtaining regulatory approvals to market products and ... from its development efforts; product withdrawals; competitive factors; difficulties or delays in manufacturing Millennium's products; government and ...

Environmental Power Announces Opening of New Corporate Headquarters in Tarrytown, NY

... fuels like natural gas, and our inexperience with managing such risks; difficulties involved in developing and executing a business plan; difficulties and uncertainties regarding acquisitions; technological uncertainties; ...

Palomar and Q-MED AB Enter Into International Distribution Agreement

... but are not limited to, results of future operations, technological difficulties in developing or introducing new products, the results of future research, ... the results of litigation, including patent infringement lawsuits, difficulties in collecting royalties, potential infringement of third-party ...

Millennium to Receive $40 Million Milestone Payment for Achievement of Sales Threshold for Velcade(R) (Bortezomib) for Injection

... to develop and commercialize products and services based on its work; difficulties or delays in obtaining regulatory approvals to market products and ... from its development efforts; product withdrawals; competitive factors; difficulties or delays in manufacturing the Company's products; government and ...

Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights

... resources, its ability to successfully develop and market products, difficulties or delays in its preclinical studies or clinical trials, difficulties or delays in manufacturing its clinical trials materials, the scope and ...

Life Sciences Leader Joins Millennium Board of Directors

... to develop and commercialize products and services based on its work; difficulties or delays in obtaining regulatory approvals to market products and ... from its development efforts; product withdrawals; competitive factors; difficulties or delays in manufacturing the Company's products; government and ...

Pressure BioSciences, Inc. Provides Corporate Update

... the possibility that the Company may encounter unforeseen technological difficulties in the development of the PCT technology, the possibility that the ... market as a needed improvement over current extraction methods, or other difficulties that would prevent or otherwise impair the Company's ability to install at ...

NeurogesX Reports Second Quarter 2009 Results

... if approved, or the inability of physicians to obtain sufficient reimbursement for procedures associated with NeurogesX' products; and other difficulties or delays in, clinical development of, and obtaining regulatory approval for NeurogesX' product candidates. For further information regarding these ...

Curis and Debiopharm Sign an Exclusive License Agreement Covering the HSP90 Inhibitor CUDC-305

... of GDC-0449, and Debiopharm may not be able to successfully advance CUDC-305 into clinical trials as planned. - Curis may experience difficulties or delays in obtaining or maintaining required regulatory approvals for products under development both internally and through its ...

NeurogesX Announces New PDUFA Date for Qutenza(TM) New Drug Application

... side effects or inadequate therapeutic efficacy or tolerability; physician or patient reluctance to use Qutenza or NGX-1998, if approved; and other difficulties or delays in, clinical development of, and obtaining regulatory approval for NeurogesX' product candidates. For further information regarding these ...

ADVENTRX Pharmaceuticals Announces Financing

... Code; the risk that, if ADVENTRX liquidates its assets, the capital available for distribution to stockholders, if any, will be insignificant; difficulties or delays in manufacturing, obtaining regulatory approval for and marketing ANX-530 and ANX-514, including validating commercial manufacturing ...

NxStage Reports Second Quarter 2009 Financial Results

... performance or achievements, including market acceptance and demand for NxStage's products, growth in home and/or daily hemodialysis, unanticipated difficulties in achieving operational efficiencies and cost reductions, changes in reimbursement for home and daily hemodialysis, changes in the regulatory ...

Oramed Pharmaceuticals was Awarded a NIS 3.1 Million Grant From the Israeli Office of the Chief Scientist

... including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval for our product candidates; competition from other pharmaceutical or biotechnology companies; and the ...

DOR BioPharma Receives FDA Orphan Drug Designation for orBec(R) for the Treatment of Chronic Gastrointestinal GVHD

... cash expenditures will not exceed projected levels, that product development and commercialization efforts will not be reduced or discontinued due to difficulties or delays in clinical trials or due to lack of progress or positive results from research and development efforts, that it will be able to ...

Purdue Pharmaceutical Products L.P. and Transcept Pharmaceuticals, Inc. Sign Exclusive Agreement to Commercialize Intermezzo(R) in the United States

... to commercialization of Intermezzo ((R)); obtaining, maintaining and protecting the intellectual property incorporated into Intermezzo ((R)); other difficulties or delays in the commercialization of Intermezzo ((R)), carrying out activities or obtaining payments under the Collaboration Agreement and clinical ...

Terrosa Technologies Assigned as Exclusive Reseller for Inclinicalperform CTMS/SaaS Clinical Trials Collaboration Software

... We bring process automation to clinical operations in the pharmaceutical, biotechnology and medical device industries. After encountering all the difficulties of implementing other leading clinical software programs, we realized that the cost of implementation and lost time for stakeholders to learn new ...

Bacteria pack their own demise

... forms they take while in action a difficult feat to pull off, requiring the simultaneous use of a whole range of different technologies. One of the difficulties for instance lay in the fact that part of the antitoxin lacks a fixed structure. This formlessness keeps it from being brought into view. Future ...

NeurogesX to Hold Conference Call to Discuss Second Quarter 2009 Financial Results

... indications; NeurogesX' product candidates may have unexpected adverse side effects or inadequate therapeutic efficacy or tolerability; and other difficulties or delays in, clinical development of, and obtaining regulatory approval for NeurogesX' product candidates. For further information regarding these ...
Other Contents
(Date:4/17/2014)... Cell Press journal Current Biology on April ... sex lives. The Brazilian insects, which represent four distinct ... are the first example of an animal with sex-reversed ... in several different animals, Neotrogla is the ... reversed," says Kazunori Yoshizawa from Hokkaido University in Japan. ...
(Date:4/17/2014)... the immune system may fight cancers and viral infections. ... to treat illness. , The research, in mice, suggests ... police" specialized squads of defenders that patrol only ... city, the body. , Scientists at Washington University School ... liver, skin and uterus each has dedicated immune cells, ...
(Date:4/16/2014)... museum collections two new species of yellow-shouldered bats have been unearthed ... Field Museum of Natural History and described in the open access ... the genus Sturnira are part of a recent discovery ... third one still waiting to be officially announced. , Up until ...
Breaking Biology News(10 mins):In sex-reversed cave insects, females have the penises 2Some immune cells defend only 1 organ 2Two new species of yellow-shouldered bats endemic to the Neotropics 2
(Date:4/17/2014)... MD, was recently invited to submit a review ... Microbiology , one of the world,s foremost scientific ... specialist, and chair of the Department of Pediatrics ... analyzed the epidemiology and microbiology of co-infections during ... as more recent 2009 novel H1N1 pandemic. ...
(Date:4/17/2014)... 17, 2014) Doctors who treat patients with ... (LAM) can face an agonizing treatment decision. , ... disease and help relieve shortness of breath. But ... sirolimus can cause potentially fatal complications following transplantation. ... Daniel Dilling, medical director of Loyola University Medical ...
(Date:4/17/2014)... Colic affects about one in five infants in the ... during the first several months after birth. Research into ... promise; however, the April 1, 2014 issue of the ... on a study, "Probiotics and Infant Colic," concluding that ... for infant colic did not reduce crying or ...
(Date:4/17/2014)... 17, 2014 EcoHealth Alliance, a nonprofit organization that ... a comprehensive review today examining the current state of ... review calls for improved global surveillance strategies to combat ... outbreak of Ebola in West Africa that has claimed ... Guinea and Liberia. According to the World Health ...
(Date:4/17/2014)... A. Arias, M.D., Ph.D., at The University of Texas ... new superbug that caused a bloodstream infection in a ... issue of The New England Journal of Medicine ... class of highly-resistant bacteria known as methicillin-resistant Staphylococcus ... of hospital and community-associated infections. The superbug has also ...
Breaking Medicine News(10 mins):Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 3Health News:New MRSA superbug emerges in Brazil 2
Other TagsOther Tags